Source: Curia
Market Herald logo


Be the first with the news that moves the market
  • Island Pharmaceuticals (ILA) enters one-off purchase deal with Curia, Inc.
  • The deal covers the manufacturing of a GMP drug substance for ILA’s phase 2a clinical trial, which will test its lead drug candidate against dengue fever
  • This replaces an agreement between ILA and CerRx, Inc. made in July, which was cancelled at no cost to Island following an inventory error
  • Shares are down 6.85 per cent to 34 cents each at 4:02 pm AEST

Island Pharmaceuticals (ILA) has entered a one-off purchase deal with Curia, Inc.

Based in Melbourne, Island is a clinical-stage drug repurposer focussed on antiviral therapeutics for infectious diseases. Its lead asset, ISLA-101, has been repurposed for the prevention and treatment of mosquito-borne diseases.

The agreement covers the manufacturing of two 2.5-kilogram de novo batches of GMP drug substance for ILA’s upcoming phase 2a clinical trial, in which ISLA-101 will be studied as a potential preventative for dengue fever.

The latest arrangement with Curia replaces a previous deal made between the company and CerRx, Inc. in July to acquire Active Pharmaceutical Ingredient (API).

Following the July deal, Island said it was informed of an inventory error at a third-party storage facility, meaning there was less API available for purchase than originally expected.

As a result, the former agreement has been cancelled at no cost to ILA, leading the company to sign the new arrangement with Curia for around US$431,300 (A$595,500), in line with its budget forecast.

Notably, Island said the replacement manufacturing campaign would provide drug substance with a longer shelf life than that under the previous arrangement.

Island Pharmaceuticals CEO David Foster commented on the deal.

“We are happy to continue our relationship with Curia via this new manufacturing program, which will support our ISLA 101 trial in dengue fever,” Dr Foster said.

“It is pleasing to have quickly secured a new quality source for our drug substance — allowing us to continue to move forward rapidly with our phase 2a plans.”

Following the switch, company expects trial enrolment will begin early in the first quarter of 2022 rather than late in the fourth quarter of this year as previously planned.

Shares were down 6.85 per cent to 34 cents each at 4:02 pm AEST.

ILA by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.